Prudential Financial
EWTX icon

Prudential Financial’s Edgewise Therapeutics EWTX Stock Holding History

Prudential Financial’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.6M Buy
260,725
+250,120
+2,359% +$8.62M 0.01% 667
2026
Q1 		$334K Buy
+10,605
New +$306K ﹤0.01% 1990

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Prudential Financial's EWTX Position: Q2 2026 in Review

Prudential Financial increased its Edgewise Therapeutics (EWTX) stake by 2,359% in Q2 2026, buying an estimated $8.62M and bringing the position to 260,725 shares worth $10.6M. The position accounts for 0.01% of the portfolio, ranked #667.

Prudential Financial first reported a position in EWTX in Q1 2026 and has held it in 2 quarters since. 225 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Prudential Financial held 260,725 shares of Edgewise Therapeutics worth $10.6M as of Q2 2026.
  • Prudential Financial bought 250,120 Edgewise Therapeutics shares in Q2 2026, an estimated $8.62M.
  • Edgewise Therapeutics made up 0.01% of Prudential Financial's portfolio in Q2 2026, its #667 holding.
  • Prudential Financial first reported a position in Edgewise Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 225 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.